Nicotinamide riboside raises levels of NAD+, a molecule cells use to make energy and repair themselves. A clinical trial looked at whether this approach could ease long COVID fatigue and brain fog. Results showed limited differences across the whole group, but a notable number of participants improved after at least ten weeks of treatment, suggesting individual responses vary and some people may gain real benefit.
This line of work connects to broader questions about recovering human potential after illness: who responds to metabolic therapies, how long benefits last, and whether combining approaches boosts outcomes. The study opens a path toward more personalized recovery strategies and invites deeper exploration into which patients stand to gain the most. Follow the full article to see the trial details and what they might mean for people seeking clearer thinking and more energy.
Long COVID still affects people worldwide with stubborn symptoms like fatigue and cognitive issues. A clinical trial tested whether boosting NAD+ using nicotinamide riboside could help. Although overall group differences were limited, many participants showed encouraging improvements after taking NR for at least 10 weeks. The findings suggest NAD+ enhancement may offer symptom relief for some individuals.
